Teknova Q3 revenue $10.5M (+9% YoY); net loss narrows to $4.3M; reaffirms FY2025 guidance

Alpha Teknova, Inc.

2025-Q3 EPS reported -$0.23 revenue$30,536,000

Revenue $10.5M, up 9% from Q3 2024; Lab Essentials $8.3M (+16%), Clinical Solutions $1.7M (-13%).
Gross margin 30.7% vs 0.9% (Q3 2024); prior year included $2.8M non-recurring inventory charges.
Net loss $4.3M ($0.08/share) vs $7.6M ($0.15/share) a year ago; Adjusted EBITDA -$1.6M vs -$5.0M.
Free Cash Outflow $2.4M, flat YoY. Cash & short-term investments $22.1M; borrowings $13.2M.
Reaffirms FY2025 revenue guidance $39-42M and Free Cash Outflow <$12M.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-25-269488
form_type: 8-K
ticker: TKNO
cik: 0001850902
company_name: Alpha Teknova, Inc.
filed_at: 2025-11-06T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.809654+00:00
generated_at: 2026-05-16T23:59:39.284377+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-25-269488
json_url: https://secwatch.observer/filing/0001193125-25-269488.json
markdown_url: https://secwatch.observer/filing/0001193125-25-269488.md
text_url: https://secwatch.observer/filing/0001193125-25-269488.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1850902/000119312525269488/0001193125-25-269488-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1850902/000119312525269488/tkno-20251106.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-25-269488

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.